A compound of formula (I) for use in the prevention or treatment of a bacterial infection wherein: P.sup.X is selected from the group consisting of (P1), (P2) and (P3).

##STR00001##

The present invention relates to an. organic semiconductive layer which is an electron transport layer and/or an electron injection layer and/or an n-type charge generation layer, the organic semiconductive layer comprising at least one compound of formula (1) wherein R.sup.1 and R.sup.2 are each independently selected from C.sub.1 to C.sub.16 alkyl; Ar.sup.1 is selected from C.sub.6 to C.sub.14 arylene or C.sub.3 to C.sub.12 heteroarylene; Ar.sup.2 is independently selected from C.sub.14 to C.sub.40 arylene or C.sub.8 to C.sub.40 heteroarylene; R.sup.3 is independently selected from H, C.sub.1 to C.sub.12 alkyl or C.sub.10 to C.sub.20 aryl; wherein each of Ar.sup.1, Ar.sup.2 and R.sup.3 may each independently be unsubstituted or substituted with at least one C.sub.1 to C.sub.12 alky group; n is 0 or 1; and m is 1 in case of n=0; and m is 1 or 2 in case of n=1, phosphine oxide compounds comprised therein and to organic electroluminescent devices comprising such layers and compounds.

##STR00001##

The present invention relates to a novel class of benzimidazolyl/imidazolyl phosphine ligands, methods of preparing such ligands via a simple one-pot protocol, and applications of the ligands in catalytic reactions.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention relates electroluminescent devices, comprising a compound of the formula

##STR00001##

especially as host for phosphorescent compounds. The hosts may function with phosphorescent materials to provide improved efficiency, stability, manufacturability, or spectral characteristics of electroluminescent devices.

A heteroleptic binuclear copper(I) complex of the Cu.sub.2X.sub.2(E?N*)L.sub.2 form, having a structure of formula A: ##STR00001##
The copper(I) complex may be used in optoelectronic components, particularly for use in organic light emitting diodes (OLEDs).

A phosphinimide catalyst system comprises: i) a phosphinimide pre-polymerization catalyst having a cyclopentadienyl ligand and a phosphinimide ligand which is substituted with a guanidinate type group; and ii) a catalyst activator. The catalyst system polymerizes ethylene with an alpha-olefin to give high molecular weight ethylene copolymer.

A triphenylphosphine oxide derivative is described, which is applied to a phosphorescence host and an electron transport material. R in a structural formula of the triphenylphosphine oxide derivative is H or a substituent group with an electron transporting property. An electrophosphorescent luminescent device is further described. An electron mobility and a luminous efficiency of a light emitting device are improved and a roll-off efficiency of the light emitting device is reduced by all using H or substituent groups with electron transporting properties as R groups of the triphenylphosphine oxide derivative.

A genus of compounds encompassed by formula (III) and their use is disclosed: ##STR00001## The compounds activate Ppargc1a and, as a consequence, are useful for treating a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, motor neuron diseases, and a demyelinating disease.

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I):

##STR00001##

Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.